COMP <GO>
GBX vs TMO // DIVIDEND YIELD & FCF PAYOUT SAFETY
Greenbrier Companies Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: GBX 4
— TMO 6
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: GBX
LAST: $38.53 (+2.80%) • MKT CAP: $1.19B
dividend-safety
3.32%
LAST: $709.18 (+0.71%) • MKT CAP: $262.22B
dividend-safety
0.24%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GBX VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GBX | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 18.70% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 24.10% | 9.30% | +14.80 | GBX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 30.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 22.25% | 2.40% | +19.85 | GBX | /fcf-yield <GO> |
| Operating Margin | 11.10% | 17.40% | -6.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.30% | 15.10% | -8.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | -8.60% | 3.90% | -12.50 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 3.32% | 0.24% | +3.08 | GBX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 4.50 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.2 | 62.9 | -16.72 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.94 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 5.5x | 36.3x | -30.80 | GBX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.19B | $262.22B | -$261.02B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GBX REV | TMO REV | GBX GROSS % | TMO GROSS % | GBX FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.24B | $44.56B | 18.7% | — | $265.7M | $6.29B |
| FY 2024 | $3.54B | $42.88B | 15.8% | — | $329.6M | $7.27B |
| FY 2023 | $3.94B | $42.86B | — | — | $71.2M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GBX // BETA —
TMO // BETA 0.94